TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01557582

Intervention type: DEVICE
Group type: OTHER
Intervention: Ventripoint Medical System
Description: The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images.
Study: NCT02717078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Therapy
Description: The intervention for both study groups will be a change in diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Therapy
Description: The intervention for both study groups will be a change in diet.
Study: NCT03952585

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Receive FDG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study: NCT04035109

Intervention type: DRUG
Group type: OTHER
Intervention: Anakinra
Description: A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.

Intervention type: DRUG
Group type: OTHER
Intervention: Anakinra
Description: A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.

Intervention type: DRUG
Group type: OTHER
Intervention: Preservative-free 0.9% sodium chloride (Placebo)
Description: A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.

Intervention type: DRUG
Group type: OTHER
Intervention: Preservative-free 0.9% sodium chloride (Placebo)
Description: A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: House dust mite allergen
Description: Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: House dust mite allergen
Description: Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cat hair allergen
Description: Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cat hair allergen
Description: Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
Study: NCT00963131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antioxidants tablets
Description: vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: antioxidants tablets
Description: vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
Study: NCT00167648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide or goserelin
Description: Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Description: Estradiol patches, six at 0.1 mg each, changed every 3-4 days
Study: NCT01796483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clonidine (Catapressan)
Description: Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine (Catapressan)
Description: Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo 90 minutes before EEG
Description: Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 90 minutes before EEG
Description: Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
Study: NCT03308786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin-2
Description: Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles
Study: NCT03374969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-Up
Description: Attachment and Biobehavioral Catch-up (ABC) is a 10-session, weekly intervention delivered in the family's home. ABC addresses three primary issues. First, young children who have experienced early adversity are especially in need of nurturance and parents who behave in synchronous ways and delight in them. Next, when parents behave in frightening ways, it is difficult for children to look to them for reassurance when distressed. This can be particularly difficult for children who have experienced early adversity. Therefore, this intervention helps parents learn how to: 1) behave in nurturing ways when children are distressed; 2) behave in synchronous, delighted ways when children are not distressed; and 3) avoid behaving in frightening or intrusive ways. Interventionists are provided with a manualized protocol, but tailor specific session content to each family's needs. Sessions are videotaped, both for playback to families, and for supervision.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education for Families
Description: Developmental Education for Families (DEF) is a 10-session, weekly intervention delivered in the family's home. DEF focuses on enhancing gross and fine motor skills, cognition and language development. The age-based protocols (i.e., 6-24 months,) provide information about the developmental themes of focus for each week and suggest activities to enhance the target skills for that week. However, the protocols do not provide a direct script with which to conduct the sessions. Interventionists tailor the developmental program session to the needs of the child and family by considering the child's current gross, fine, cognitive and language skills and creatively preparing several activities that will address the session topics.
Study: NCT02850107

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic HawkOne® or TurboHawk™
Description: Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic IN.PACT® Admiral® DCB
Description: FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic Spider™ Distal Protection Device (DPD)
Description: It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).

Intervention type: DEVICE
Group type: OTHER
Intervention: Volcano Visions® PV .014 IVUS catheter
Description: Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nitinol Stent Placement
Description: Only FDA approved nitinol stents can be used if provisional stenting is required.
Study: NCT03196856

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance and Plyometric Exercise
Description: 12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance and Plyometric Exercise
Description: 12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greek Yogurt (0% Plain)
Description: 200g 3x/day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Study Designed Supplement
Description: Iso-energetic to yogurt. 3x/day for 12 weeks.
Study: NCT01138774

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Double blind dietary intervention with EPA and lipoic acid
Description: Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Double blind dietary intervention with EPA and lipoic acid
Description: Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Double blind dietary intervention with EPA and lipoic acid
Description: Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Double blind dietary intervention with EPA and lipoic acid
Description: Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
Study: NCT03676192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-16
Description: 15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: 15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
Study: NCT03698409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preserved saline in reconstitution of Botox
Description: The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
Study: NCT00134030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study: NCT00578617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Diltiazem 180-240mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Verapamil 180-240mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Digoxin 0.125mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm Control
Description: Propafenone 450mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Flecainide 200mg
Study: NCT00134030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: Given subcutaneously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo amputation or limb salvage surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo amputation or limb salvage surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo amputation or limb salvage surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo amputation or limb salvage surgery
Study: NCT04259320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beeswax containing barrier
Description: Use beeswax containing barrier on each nipple after each breastfeeding.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Breast milk
Description: Apply breast milk on each nipple and areola after each breastfeeding.
Study: NCT01223131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous
Study: NCT04967378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEPPI
Description: 10 weekly individual sessions, 90 minutes each, at the participants' homes. The content of sessions includes psychoeducation, cognitive training, psychotherapeutic intervention, and compensatory strategy training.
Study: NCT01538511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
Study: NCT01323959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BoostrixTM Polio
Description: Single dose, intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BoostrixTM Polio
Description: Single dose, intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BoostrixTM Polio
Description: Single dose, intramuscular administration.
Study: NCT00578617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Sotalol 240mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Dofetilide 500mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Amiodarone 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Quinidine 600-900mg
Study: NCT02754011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of ribociclib + capecitabine
Description: RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
Study: NCT00872417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)
Description: use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: second line ARV therapy (3TC+TDF+LPV/RTV)
Description: Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
Study: NCT02046616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg will be administered subcutaneously QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Biologic DMARDs
Description: Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
Study: NCT02153606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin Suppository
Description: The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Suppository
Description: Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
Study: NCT02595398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg CLS-TA Suprachoriodal Injection
Description: CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham procedure administered at 2 timepoints
Study: NCT00680472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HKT-500 Ketoprofen Topical Patch
Description: HKT-500 Ketoprofen Topical Patch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Treatment with Placebo Patch